摘要
目的验证血脂康在对高脂血症合并脑梗死病人的降血脂作用及通过观察卵磷脂胆固醇脂酰转移酶(Lecithin cholesterol acyltransferase,LCAT)活性的变化探讨其作用机理。方法65例CT或MRI证实脑梗死患者,血脂符合高脂血症标准,随机分为两组,分别给予血脂康0.6g口服2次/d及安慰剂治疗60d后评估血脂及LCAT活性的变化。结果治疗组甘油三脂、胆固醇、LDL水平较治疗前下降,与对照组相比有统计学意义。LCAT上升在治疗组有统计学意义。结论血脂康在高血脂的脑梗死病人中具有明显降低血脂的作用,其机理可能通过升高LCAT水平而达到降血脂的目的。
Objective To evaluate the effect of Xuezhikang on serum lipids and LCAT of patients with cerebral infarction and hyperlipidemia and to find out the mechanism of Xuezhikang. Methods 65 patients with cerebral infarction and hyper lipidemia were randomly treated with Xuezhikang（32 cases） and placebo（33 cases） for 60 days. The serum level of hpids and LCAT were examined before and after the treatment. Results The serum levels of TG, TC and LDL decreased and LCAT increased significantly compared with those of control. Conclusion Xuezhikang has effects on the therapy of hyperlipidemia in patients with cerebral ischemia without adverse effect. Rise of LCAT may be the key in the effect of Xuezhikang.
出处
《中国微循环》
北大核心
2006年第3期208-209,共2页
Journal of Chinese Microcirculation
